GSK3B and colorectal carcinoma: Notably, GSK3B inhibition rendered the resistant cell lines sensitive to gedatolisib, both in vitro and in mouse xenografts, suggesting that GSK3B targeting may be a strategy to overcome the resistance of PIK3CA- and TCF7-mutant CRC to PI3K/mTOR-targeted therapies [71].